Aβ/tau aggregation-IN-1 is primarily used in research focused on neurodegenerative diseases, particularly Alzheimer's disease. It functions as an inhibitor of amyloid-beta (Aβ) and tau protein aggregation, which are key pathological features of the disease. By preventing the aggregation of these proteins, it helps in studying their role in neurodegeneration and the progression of Alzheimer's. This compound is valuable in developing potential therapeutic strategies aimed at reducing or halting the formation of toxic protein aggregates in the brain. Researchers use it to explore mechanisms of protein misfolding and to screen for compounds that could lead to effective treatments for Alzheimer's and related disorders.